The success of copyright’s blockbuster initially drove a boom for pharma, nevertheless recent changes present a murky outlook for shareholders. Lower-cost versions are reducing revenue, and persistent legal battles add more complexity to the landscape. While some companies may still benefit from related services, the overall trend suggests a war… Read More